ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GSK Gsk Plc

1,638.50
-2.00 (-0.12%)
Last Updated: 13:44:10
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -0.12% 1,638.50 1,637.50 1,638.50 1,647.00 1,634.00 1,638.50 778,682 13:44:10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.70 67.52B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,640.50p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £67.52 billion. Gsk has a price to earnings ratio (PE ratio) of 13.70.

Gsk Share Discussion Threads

Showing 15501 to 15523 of 33100 messages
Chat Pages: Latest  628  627  626  625  624  623  622  621  620  619  618  617  Older
DateSubjectAuthorDiscuss
03/11/2017
11:43
Agree Luke Miels was a big gain, and needed to sharpen-up on improved commercial and faster application in the pharma sector. Quite a productive and positive development for GSK, and the changes should be seen as constructive and welcome by the Institutions...certainly not a negative.
cyberian
03/11/2017
11:34
Cyberian, I would much prefer Mr Miles in the top R&D job.
He played a major role in the rejuvenation of AZN and their oncology pipeline,
so little wonder Emma poached him.

The AZN CEO was reportedly furious at Lukes departure.

essentialinvestor
03/11/2017
11:29
Just as easy for the government to pay Two People for doing the same Job as One, it's only taxpayer cash after all!
gbh2
03/11/2017
11:27
EI...agree pretty clear that he is going to take up a senior role with the UK Government, and EM appears to have recruited his replacement by her recent poaching of AZ. pharma expert. Maybe I am wrong but probably a reasonable move all round, and one that should not spook the market at all.
cyberian
03/11/2017
10:50
FT reporting Vallance may be on his way out, GSK refusing to comment.
essentialinvestor
03/11/2017
09:12
3m buy looking at chart before 9am?
che7win
03/11/2017
08:46
FAB, if you are about, what price are you looking for here?. Many thanks.
essentialinvestor
03/11/2017
08:03
NHS to fast track drugs
marine boy
03/11/2017
07:08
Yesterday's much weaker GBP/USD and wider UKX strength were both supportive,
so would imagine without those GSK would have traded lower as per Thursday's early
price action.

essentialinvestor
03/11/2017
07:00
You may be right Fab, but why?
jadeticl3
03/11/2017
00:58
Bit further to go for me.
fabius1
03/11/2017
00:25
These shares are a bloody nice gift, along with a lovely divi, more than happy to scoop up more. GLA
ny boy
03/11/2017
00:18
posts 15480/1 are both excellent, and hit the spot, especially over the comment as to where we were on the share price on 24/10. WS close was equiv. to 1377p, but the variance of 20p is almost always the case.
cyberian
02/11/2017
23:16
@unastubbs

All big consumer healthcare companies will of course "consider" the Pfizer, and Merck for that matter, assets. Finance only comes into play if things get serious. Companies like GSK and RB will always look for synergies and potential opportunities. My point is that analysts on the recent call simply got her to state the obvious, went away and wrote up notes saying the dividend was under threat and the share price fell 10%.

I feel analysts are over concerning themselves with EW consumer background when her actions to date say she is very much focused on the pharma business.

What would I know anyway, only been doing this twenty years.

romeike
02/11/2017
22:37
I think this current price is stupid! It is far too low without real justification.
Analysts are not forecasting they are merely like meteorologists who look out of the window and “forecast̶1; rain because they see it is raining.
Compare the market price on 24th October with now. What real data has been released since then? Does any of this justify such a fall? I think not. So, despite having far too many of these, I keep adding because I cannot believe there is justification for such a drop. Not to mention almost 6% dividend!

jadeticl3
02/11/2017
15:58
I thought about it but luckily thought better of it. Happy with GSK - I hope! :-)
hubshank
02/11/2017
15:56
I agree with you there Monty ..although I did do a bit of a gamble ..bought yesterday 260 out straightaway this morning at 267 ..in hindsight it was a bit daft of me to have tried the trade
badtime
02/11/2017
15:31
BT I would touch with a 20 foot barge pole.
montyhedge
02/11/2017
15:23
Looks like I made the right choice! BT not for me - GSK all the way!
hubshank
02/11/2017
15:13
Oh ok, getting excited, lol
montyhedge
02/11/2017
15:01
Monty u r repeating yourself now re price .. see your post a few hours ago :)))
badtime
02/11/2017
14:46
Should recover some of that market cap so 1450p possible. Ex div 9th Nov 19p in the bag.
montyhedge
02/11/2017
13:24
Loso
Yes she was naive, but cost £8 billion in market cap value. In 3 days, lol.

montyhedge
Chat Pages: Latest  628  627  626  625  624  623  622  621  620  619  618  617  Older

Your Recent History

Delayed Upgrade Clock